

Author(s): Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.

Question: Should Itraconazole compared to Standard treatment be used for COVID-19 patients?

Setting: Inpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Itraconazole	Standard treatment	Relative (95% CI)	Absolute (95% CI)	

All-cause mortality

1 ¹	randomised trials	serious ^a	not serious	not serious	very serious ^b	none	No deaths reported				⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	--------------------	--	--	--	------------------

Number of patients discharged

1 ¹	randomised trials	serious ^a	not serious	not serious	very serious ^b	none	22/32 (68.8%)	21/33 (63.6%)	RR 1.08 (0.76 to 1.53)	51 more per 1.000 (from 153 fewer to 337 more)	⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	---------------	---------------	-------------------------------	---	------------------

Duration of hospitalization in intensive care

1 ¹	randomised trials	serious ^a	not serious	not serious	very serious ^b	none	HR: 0.76 [IC95% (0.34; 1.70)] p=0.50				⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	--------------------------------------	--	--	--	------------------

Length of stay in hospital

1 ¹	randomised trials	serious ^a	not serious	not serious	very serious ^b	none	HR: 0.92 [IC95% (0.55; 1.54)] p=0.75				⊕○○○ VERY LOW
----------------	-------------------	----------------------	-------------	-------------	---------------------------	------	--------------------------------------	--	--	--	------------------

Explanations

- a. Downgraded of one level for high risk of performance bias and unclear risk of selection bias
- b. Downgraded of two levels for very small sample size

References

1. Liesenborghs L, Spriet I, Jochmans D, Belmans A, Gyselinck I, Teuwen L-A, et al. Itraconazole for COVID-19: Preclinical Studies and a Proof-of-Concept Pilot Clinical Study. SSRN Electronic Journal. 2020.